# RAG evaluation on dev (15 answerable + Q24)

Pipeline {'parser_version': 'v1.2', 'doc_version': 'v1', 'tokenizer': 'v2'}; model Qwen/Qwen3-4B-Instruct-2507; grades from qrels v1.2 (not shown to the model; None = unjudged).

## Q01: Recruiting NSCLC trials involving pembrolizumab

| NCT ID | Title | Grade |
|---|---|---|
| NCT06195527 | PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in N | 2 |
| NCT07061379 | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line set | 2 |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive M | 0 |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminar | 1 |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advance | 0 |

Partial matches:

- [NCT07061379](https://clinicaltrials.gov/study/NCT07061379): Includes pembrolizumab in first-line NSCLC treatment with chemotherapy, but focuses on patient-reported outcomes, not specifically on pembrolizumab as the primary intervention.  
- [NCT05761223](https://clinicaltrials.gov/study/NCT05761223): Investigates pembrolizumab in combination with FB849, but in advanced solid tumors, not specifically NSCLC.  
- [NCT03829254](https://clinicaltrials.gov/study/NCT03829254): Includes pembrolizumab in combination with NUC-7738, but in advanced solid tumors and lymphoma, not NSCLC.

None of the retrieved trials specifically study pembrolizumab as a standalone or primary intervention in NSCLC.

As match: [] · partial: ['NCT07061379', 'NCT05761223', 'NCT03829254'] · no-match mention: [] · says no match: False

## Q02: Phase 3 breast cancer trials

| NCT ID | Title | Grade |
|---|---|---|
| NCT04193722 | The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxi | 2 |
| NCT00003418 | Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Ca | 2 |
| NCT02000622 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Che | 2 |
| NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administrat | 2 |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Recepto | 2 |

Phase 3 trials for breast cancer:

- The Effect of Hyperbaric Oxygen Therapy on Breast Cancer Patients With Late Radiation Toxicity - UMBRELLA HONEY Trial evaluates hyperbaric oxygen therapy in breast cancer patients with radiation toxicity [NCT04193722].  
- Exemestane compared with tamoxifen in postmenopausal women with primary breast cancer [NCT00003418].  
- Olaparib monotherapy versus chemotherapy in metastatic breast cancer with germline BRCA1/2 mutations [NCT02000622].  
- A study evaluating subcutaneous pertuzumab and trastuzumab with chemotherapy in HER2-positive early breast cancer [NCT03493854].  

Partial matches: NCT02107703 includes hormone receptor-positive HER2-negative breast cancer but is not recruiting.

As match: ['NCT04193722', 'NCT00003418', 'NCT02000622', 'NCT03493854'] · partial: ['NCT02107703'] · no-match mention: [] · says no match: False

## Q03: Recruiting trials for Alzheimer's disease

| NCT ID | Title | Grade |
|---|---|---|
| NCT06914284 | Apathy-related Neurobehavioral Markers of Cognitive Decline in Old-age Bipolar Disorders:  | 0 |
| NCT06989697 | Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes | 0 |
| NCT07856472 | AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular D | None |
| NCT06906276 | Brain Activity During Complex Walking in People With Atypical Parkinsonian Syndromes | None |
| NCT04923542 | SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metasta | 0 |

None of the retrieved trials match this query. The listed trials do not focus on Alzheimer's disease, even though some involve cognitive function or aging. The conditions and interventions in the trials relate to bipolar disorder, diabetes, cardiovascular disease, Parkinsonian syndromes, and breast cancer brain metastases, not Alzheimer's disease.

As match: [] · partial: [] · no-match mention: [] · says no match: True

## Q04: Diabetes trials for adults

| NCT ID | Title | Grade |
|---|---|---|
| NCT00629434 | A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Ad | 2 |
| NCT03426423 | Diabetes and Smoking Cessation: a Gender-Oriented Study | 2 |
| NCT01910805 | Recent GDM Lifestyle Intervention | 2 |
| NCT06148259 | SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes | 2 |
| NCT06727123 | The Effect of Motivational Interviewing on Diabetes Self-Management in Diabetic Patients | 2 |

A trial studying the effect of motivational interviewing on diabetes self-management in diabetic patients [NCT06727123](https://clinicaltrials.gov/study/NCT06727123).  

Partial matches:  
- NCT00629434 compares telemedicine vs in-person diabetes education but is terminated.  
- NCT03426423 focuses on smoking cessation in type 2 diabetes, not general diabetes management.  
- NCT01910805 targets gestational diabetes, not adult type 1 or type 2.  
- NCT06148259 includes diabetes but also prostatic hyperplasia and is not focused on diabetes treatment.  

None of the retrieved trials match this query exactly for adults with diabetes receiving a diabetes-specific intervention in active recruitment or ongoing phase.

As match: ['NCT06727123'] · partial: ['NCT00629434', 'NCT03426423', 'NCT01910805', 'NCT06148259'] · no-match mention: [] · says no match: False

## Q05: Female patients with breast cancer

| NCT ID | Title | Grade |
|---|---|---|
| NCT02189278 | Improving Adherence to Recommended Surveillance in Breast Cancer Survivors | 2 |
| NCT00582803 | Adherence to Intensive Surveillance for Hereditary Breast Cancer | 2 |
| NCT05921279 | Understanding CARdiac Events in Breast Cancer | 2 |
| NCT05263362 | An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outc | 2 |
| NCT05374161 | An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) fo | 2 |

Female patients with breast cancer are studied in the following trials:

- Improving Adherence to Recommended Surveillance in Breast Cancer Survivors: This trial focuses on psychosocial intervention for breast cancer survivors, specifically targeting adherence to surveillance. [NCT02189278](https://clinicaltrials.gov/study/NCT02189278)  
- An Intervention for Female Breast Cancer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain: This trial targets female breast cancer patients with depression and pain using Acceptance and Commitment Therapy. [NCT05374161](https://clinicaltrials.gov/study/NCT05374161)  

Partial matches:  
- NCT00582803 and NCT05921279 include breast cancer but do not specify female patients as the primary population.  
- NCT05263362 includes "Breast Cancer Female" but has no active intervention.  

None of the retrieved trials match this query exactly in terms of intervention and recruitment status.

As match: ['NCT02189278', 'NCT05374161'] · partial: ['NCT00582803', 'NCT05921279', 'NCT05263362'] · no-match mention: [] · says no match: False

## Q06: Phase 2 trials using immunotherapy for cancer

| NCT ID | Title | Grade |
|---|---|---|
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozanti | 2 |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocell | 2 |
| NCT07625527 | Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patient | 2 |
| NCT02688686 | Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bo | 2 |
| NCT07092696 | Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap | 2 |

Phase 2 trial testing nivolumab and ipilimumab with or without cabozantinib in metastatic or recurrent nasopharyngeal cancer [NCT05904080](https://clinicaltrials.gov/study/NCT05904080).  
Phase 2 trial evaluating ivarmacitinib, camrelizumab, and apatinib in advanced hepatocellular carcinoma with immune resistance [NCT07324473](https://clinicaltrials.gov/study/NCT07324473).  
Phase 2 trial assessing prolonged PD-1/PD-L1 inhibitor-based immunotherapy after tumor-free status in high-risk non-muscle invasive bladder cancer [NCT07625527](https://clinicaltrials.gov/study/NCT07625527).  
Phase 2 trial combining toripalimab with chemotherapy and concurrent chemoradiotherapy for cervical cancer [NCT07092696](https://clinicaltrials.gov/study/NCT07092696).  

*Note: Trial [NCT02688686] includes phase 1/2 but uses dendritic cell therapy, not standard immunotherapy.*

As match: ['NCT05904080', 'NCT07324473', 'NCT07625527', 'NCT07092696', 'NCT02688686'] · partial: [] · no-match mention: [] · says no match: False

## Q07: Observational studies for cardiovascular disease

| NCT ID | Title | Grade |
|---|---|---|
| NCT00005420 | Prediction of Quality of Life in Cardiovascular Disease | 2 |
| NCT00101530 | Improving Prevention of Heart Disease in Latinos | 2 |
| NCT07856472 | AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular D | 2 |
| NCT05626413 | Cardiovascular Disease in Patients With Diabetes: The Silesia Diabetes-Heart Project | 2 |
| NCT00374595 | Vascular Risk After Kidney Transplantation | 2 |

Observational studies for cardiovascular disease:  
[1] NCT00005420 predicts quality of life in cardiovascular disease patients.  
[2] NCT00101530 conducts an observational study on heart disease prevention in Latinos.  
[3] NCT07856472 uses retrospective ECG data analysis to study cardiovascular disease diagnosis and prognosis.  
[5] NCT00374595 examines vascular risk in patients with cardiovascular disease and chronic kidney disease.  

Partial matches:  
[4] NCT05626413 focuses on diabetes and cardiovascular disease but does not specify an observational design.

As match: ['NCT00005420', 'NCT00101530', 'NCT07856472', 'NCT00374595'] · partial: ['NCT05626413'] · no-match mention: [] · says no match: False

## Q08: Recruiting trials for metastatic cancer in adults

| NCT ID | Title | Grade |
|---|---|---|
| NCT06621173 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating | 2 |
| NCT07728942 | SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors | 2 |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Ca | 2 |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | 2 |
| NCT07238283 | Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV V | 2 |

Recruiting trials for metastatic cancer in adults:

- A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Metastatic CRC Patients [NCT06621173](https://clinicaltrials.gov/study/NCT06621173)  
- SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors [NCT07728942](https://clinicaltrials.gov/study/NCT07728942)  
- A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors [NCT07232420](https://clinicaltrials.gov/study/NCT07232420)  
- AK129 Combination Therapy for Advanced Solid Tumors [NCT06943820](https://clinicaltrials.gov/study/NCT06943820)  

Partial matches:  
- NCT07238283 focuses on first-line treatment of metastatic pancreatic cancer, not broad metastatic cancer.

As match: ['NCT06621173', 'NCT07728942', 'NCT07232420', 'NCT06943820'] · partial: ['NCT07238283'] · no-match mention: [] · says no match: False

## Q09: Phase 1 trials involving targeted therapy for solid tumors

| NCT ID | Title | Grade |
|---|---|---|
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | 0 |
| NCT06001580 | A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors | 2 |
| NCT03053466 | APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | 0 |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | None |
| NCT04586270 | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | 2 |

A Phase 1 trial studying AK129 combination therapy in advanced solid tumors, including non-small cell lung cancer, HNSCC, and colorectal adenocarcinoma [NCT06943820](https://clinicaltrials.gov/study/NCT06943820).  

Partial matches:  
- NCT06001580: Phase 1 trial of BR101 in advanced solid tumors, but completed.  
- NCT03053466: Phase 1 trial of APL-501 in select solid tumors with MSI/dMMR, completed.  
- NCT04597541: Phase 1/2 trial of AK112 in solid tumors, completed.  
- NCT04586270: Phase 1 trial of TAS0612 in advanced solid tumors, terminated.  

None of the trials are currently recruiting and only one (NCT06943820) involves a targeted therapy (AK129) in a broad solid tumor population with active recruitment.

As match: ['NCT06943820'] · partial: ['NCT06001580', 'NCT03053466', 'NCT04597541', 'NCT04586270'] · no-match mention: [] · says no match: False

## Q10: Recruiting infectious disease trials for adults

| NCT ID | Title | Grade |
|---|---|---|
| NCT05336851 | Emergency PWAS in Respiratory Infectious Disease | 2 |
| NCT07112235 | Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary  | None |
| NCT07103980 | Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough:  | 2 |
| NCT06966908 | Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection | 2 |
| NCT05977179 | Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome | 2 |

Recruiting infectious disease trials for adults:

- Studies biomarker collection in viral, bacterial, fungal, and mixed infections including pneumonia and sepsis [NCT05336851](https://clinicaltrials.gov/study/NCT05336851).  
- Investigates rhinovirus-induced COPD exacerbations to develop novel therapies [NCT07112235](https://clinicaltrials.gov/study/NCT07112235).  
- Evaluates inhaled mesenchymal stem cell-derived exosomes for post-infectious cough in adults [NCT07103980](https://clinicaltrials.gov/study/NCT07103980).  
- Focuses on hospital-based management of chronic hepatitis B virus infection in adults [NCT06966908](https://clinicaltrials.gov/study/NCT06966908).  
- Assesses dietary intervention for post-acute COVID-19 syndrome and fatigue in adults [NCT05977179](https://clinicaltrials.gov/study/NCT05977179).  

All trials are recruiting and involve adult populations with infectious disease conditions.

As match: ['NCT05336851', 'NCT07112235', 'NCT07103980', 'NCT06966908', 'NCT05977179'] · partial: [] · no-match mention: [] · says no match: False

## Q11: Keytruda trials in lung cancer

| NCT ID | Title | Grade |
|---|---|---|
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus | 2 |
| NCT03419286 | Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment | 0 |
| NCT07188480 | The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients | 0 |
| NCT03658083 | Exploring Robotic-assisted Thoracic Surgery for Lung Cancer | 0 |
| NCT02607605 | A Prospective, Observational Trial on the Diagnostic and Prognostic of LM | 0 |

None of the retrieved trials match this query. While some trials involve KEYTRUDA® (pembrolizumab) in lung cancer, none specifically study Keytruda as the primary intervention in lung cancer. Trial [1] includes pembrolizumab (KEYTRUDA®) in combination with chemotherapy for metastatic NSCLC, but it does not focus on Keytruda as the sole or primary treatment. The other trials do not involve Keytruda or are not relevant to lung cancer treatment with Keytruda.

As match: [] · partial: [] · no-match mention: [] · says no match: True

## Q18: Pediatric epilepsy trials

| NCT ID | Title | Grade |
|---|---|---|
| NCT01450423 | Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy | 2 |
| NCT00044278 | Pediatric Epilepsy Study in Subjects 1-24 Months | 2 |
| NCT03836924 | A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctiv | 2 |
| NCT05864846 | A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On | 0 |
| NCT03406702 | CX-8998 for Absence Seizures | 2 |

[2] NCT00044278 studies lamotrigine in pediatric patients with epilepsy aged 1–24 months.  
[3] NCT03836924 assesses perampanel as adjunctive treatment for partial onset seizures in participants aged 12 years or older with epilepsy.  

Partial matches:  
[1] NCT01450423 involves juvenile myoclonic epilepsy and physical activity, not a standard pediatric epilepsy trial.  
[5] NCT03406702 targets absence seizures in epilepsy but lacks specific pediatric focus.  
[4] NCT05864846 focuses on tuberous sclerosis complex, not general pediatric epilepsy.  

None of the retrieved trials match this query exactly in terms of broad pediatric epilepsy population and intervention.

As match: ['NCT00044278', 'NCT03836924'] · partial: ['NCT01450423', 'NCT03406702', 'NCT05864846'] · no-match mention: [] · says no match: False

## Q20: Parkinson's disease trials that are not yet recruiting

| NCT ID | Title | Grade |
|---|---|---|
| NCT06809556 | Association of EEG Parameters with Postoperative Delirium in Patient's with Parkinson's Di | 2 |
| NCT07361627 | Upper Limb Rehabilitation Using Non-invasive Spinal Cord Stimulation | 0 |
| NCT07720479 | Intranasal Insulin for Postoperative Delirium in Older Patients With T2DM | 0 |
| NCT04158024 | Erector Spinae Plane Block in Congenital Heart Disease Patients | None |
| NCT06558422 | Human Models of Selective Insulin Resistance: Pancreatic Clamp | 0 |

None of the retrieved trials match this query. While several trials list Parkinson's disease as a condition, none specifically study Parkinson's disease and are not yet recruiting with a relevant intervention for Parkinson's disease. The trials either focus on postoperative delirium, spinal cord injury, or metabolic conditions, and do not target Parkinson's disease with interventions relevant to its treatment.

As match: [] · partial: [] · no-match mention: [] · says no match: True

## Q22: Which pembrolizumab studies for non-small cell lung cancer are currently enrolling patients?

| NCT ID | Title | Grade |
|---|---|---|
| NCT06195527 | PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in N | 2 |
| NCT07061379 | Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line set | 2 |
| NCT07229729 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-sma | 0 |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advance | 0 |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Ca | 0 |

None of the retrieved trials match this query. While several trials involve pembrolizumab and non-small cell lung cancer (NSCLC), none specifically study pembrolizumab as the sole or primary intervention for NSCLC and are currently enrolling patients. Trial [2] includes pembrolizumab but focuses on patient-reported outcomes and combines it with chemotherapy, not as a standalone pembrolizumab study. The other trials either use different drugs or do not focus on pembrolizumab as the primary intervention.

As match: [] · partial: [] · no-match mention: [] · says no match: True

## Q23: Non-interventional cardiovascular disease studies

| NCT ID | Title | Grade |
|---|---|---|
| NCT07856472 | AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular D | 2 |
| NCT00005420 | Prediction of Quality of Life in Cardiovascular Disease | 2 |
| NCT00101530 | Improving Prevention of Heart Disease in Latinos | 2 |
| NCT00374595 | Vascular Risk After Kidney Transplantation | 2 |
| NCT01303900 | Cardiovascular Disease (CVD) in Haemophilia | 2 |

[1] NCT07856472 studies the use of AI-powered electrocardiography for diagnosis and prognostic prediction in cardiovascular disease using retrospective ECG data. [NCT07856472](https://clinicaltrials.gov/study/NCT07856472)

Partial matches:  
[2] NCT00005420, [3] NCT00101530, [4] NCT00374595, and [5] NCT01303900 involve cardiovascular disease but lack interventions and are non-interventional in design; however, they do not specifically focus on cardiovascular disease studies as a primary non-interventional investigation.  

None of the retrieved trials match this query exactly as they either lack a defined intervention or are not explicitly non-interventional cardiovascular disease studies.

As match: ['NCT07856472'] · partial: ['NCT00005420', 'NCT00101530', 'NCT00374595', 'NCT01303900'] · no-match mention: [] · says no match: False

## Q24: Phase 3 trials of lecanemab for early Alzheimer's disease

| NCT ID | Title | Grade |
|---|---|---|
| NCT06989697 | Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes | 0 |
| NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administrat | 0 |
| NCT03108846 | Escitalopram for Agitation in Alzheimer's Disease | 0 |
| NCT00004645 | Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Sev | 0 |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Recepto | 0 |

None of the retrieved trials match this query. The query specifically asks for Phase 3 trials of lecanemab for early Alzheimer's disease, but none of the listed trials involve lecanemab or focus on early Alzheimer's disease. The closest trial (NCT03108846) studies escitalopram for agitation in dementia, not lecanemab, and does not target early Alzheimer's disease.

As match: [] · partial: [] · no-match mention: ['NCT03108846'] · says no match: True

